```
L1            1 S US 20070142403/PN

     FILE 'REGISTRY' ENTERED AT 13:35:33 ON 28 DEC 2009
L2            1 S 676128-37-3/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 13:36:06 ON 28 DEC 2009
L3            1 S 676127-99-4/RN
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 13:38:02 ON 28 DEC 2009
L4              STRUCTURE UPLOADED
L5           50 S L4 SSS SAM
L6         1133 S L4 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 13:39:04 ON 28 DEC 2009
L7          359 S L6

     FILE 'REGISTRY' ENTERED AT 13:39:53 ON 28 DEC 2009
L8              STRUCTURE UPLOADED

L8      STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8              STR
```




```
L9            3 S L8 SSS SAM SUB=L6
L10          36 S L8 SSS FULL SUB=L6

     FILE 'HCAPLUS' ENTERED AT 13:41:34 ON 28 DEC 2009
L11          22 S L10
L12          11 S L11 AND (PY<2004 OR AY<2004 OR PRY<2004)

L12  ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of aminobenzodiazepinones and pharmaceutical
compositions
     containing them for use against respiratory syncytial virus
```

GI



I



II

AB Benzodiazepines (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable salts thereof, are active against respiratory syncytial virus (RSV). For I: R1 = C1-6 alkyl, aryl or heteroaryl; R2 = H or C1-6 alkyl; each R3 = halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII = H or C1-6 alkyl; n = 0-3; R4 = H or C1-6 alkyl; R6 = C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6. X = -CO-, -S(O)- or -S(O)2-; and R6 = C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C1-6 hydroxyalkyl)-, aryl-(C1-6alkyl)-O-, heteroaryl-(C1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII = H, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-. Although the methods of preparation are not claimed, .apprx.80 example prepns. are included. For example, II was prepared by N-acetylation of 3-amino-5-phenyl-1,3- dihydrobenzo[e][1,4]diazepin-2-one; the reactant was prepared by deprotection of (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3- yl)carbamic acid benzyl ester, which was prepared by cyclization of (2-aminophenyl)phenylmethanone with (benzotriazol-1-yl)(benzyloxycarbonylamino)acetic acid, which was prepared from glyoxylic acid monohydrate, benzotriazole and benzyl carbamate in toluene. Values for inhibition of RSV and toxicity were determined for >100 examples of I.

ACCESSION NUMBER: 2004:267311 HCAPLUS Full-text
DOCUMENT NUMBER: 140:287417
TITLE: Preparation of aminobenzodiazepinones and pharmaceutical compositions containing them for use against respiratory syncytial virus

INVENTOR(S): Carter, Malcolm; Henderson, Elisa; Kelsey, Richard;
Wilson, Lara; Chambers, Phil; Taylor, Debra; Tyms,
Stan
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026843	A1	20040401	WO 2003-GB4050	20030922 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499322	A1	20040401	CA 2003-2499322	20030922 <--
AU 2003267587	A1	20040408	AU 2003-267587	20030922 <--
EP 1539716	A1	20050615	EP 2003-748279	20030922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014595	A	20050809	BR 2003-14595	20030922 <--
CN 1694874	A	20051109	CN 2003-825190	20030922 <--
JP 2006503054	T	20060126	JP 2004-537305	20030922 <--
NZ 538870	A	20070427	NZ 2003-538870	20030922 <--
ZA 2005002001	A	20060628	ZA 2005-2001	20050309 <--
MX 2005002871	A	20051005	MX 2005-2871	

20050315 <--
IN 2005CN00400 A 20070406 IN 2005-CN400
20050316 <--
NO 2005001908 A 20050419 NO 2005-1908
20050419 <--
US 20060040923 A1 20060223 US 2005-528250
20050621 <--
US 7582624 B2 20090901
IN 2007CN04798 A 20080321 IN 2007-CN4798
20071026 <--
PRIORITY APPLN. INFO.: GB 2002-21923 A
20020920 <--
GB 2003-2078 A
20030129 <--
WO 2003-GB4050 W
20030922 <--
IN 2005-CN400 A3
20050316

FILE 'REGISTRY' ENTERED AT 13:45:02 ON 28 DEC 2009
L13 STRUCTURE UPLOADED

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



L14 0 S L13 SSS SAM
L15 0 S L13 SSS FULL

FILE 'HCAPLUS' ENTERED AT 13:46:03 ON 28 DEC 2009

FILE 'REGISTRY' ENTERED AT 13:46:06 ON 28 DEC 2009

FILE 'REGISTRY' ENTERED AT 13:46:35 ON 28 DEC 2009
E 103373-61-1/RN
SET EXPAND CONTINUOUS
L16 1 S E3
E 206115-23-3/RN
L17 1 S E15
E 173459-49-9/RN

L18 1 S E27

FILE 'HCAPLUS' ENTERED AT 13:50:19 ON 28 DEC 2009
L19 1 S L12 AND (SYNCYTIAL?)

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of aminobenzodiazepinones and pharmaceutical compositions
containing them for use against respiratory syncytial virus
GI



I



II

AB Benzodiazepines (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable salts thereof, are active against respiratory syncytial virus (RSV). For I: R1 = C1-6 alkyl, aryl or heteroaryl; R2 = H or C1-6 alkyl; each R3 = halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII = H or C1-6 alkyl; n = 0-3; R4 = H or C1-6 alkyl; R6 = C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6. X = -CO-, -S(O)- or -S(O)2-; and R6 = C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C1-6 hydroxyalkyl)-, aryl-(C1-6alkyl)-O-, heteroaryl-(C1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII = H, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-. Although the methods of preparation are not claimed, .apprx.80 example prepns. are included. For example, II was prepared by N-acetylation of 3-amino-5-phenyl-1,3- dihydrobenzo[e][1,4]diazepin-2-one; the reactant was prepared by deprotection of (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3- yl)carbamic acid benzyl ester, which was prepared by cyclization of (2-aminophenyl)phenylmethanone with (benzotriazol-1-yl)(benzyloxycarbonylamino)acetic acid, which was prepared from glyoxylic acid monohydrate, benzotriazole and benzyl carbamate in

toluene. Values for inhibition of RSV and toxicity were determined for >100 examples of I.

ACCESSION NUMBER: 2004:267311 HCAPLUS Full-text
DOCUMENT NUMBER: 140:287417
TITLE: Preparation of aminobenzodiazepinones and pharmaceutical compositions containing them for use against respiratory syncytial virus
INVENTOR(S): Carter, Malcolm; Henderson, Elisa; Kelsey, Richard; Wilson, Lara; Chambers, Phil; Taylor, Debra; Tyms, Stan
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026843	A1	20040401	WO 2003-GB4050	20030922 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

FILE 'REGISTRY' ENTERED AT 13:51:50 ON 28 DEC 2009
L20 STRUCTURE UPLOADED

L20 STRUCTURE UPLOADED

=> d l20
L20 HAS NO ANSWERS
L20 STR



L21 0 S L20 SSS SAM
L22 4 S L20 SSS FULL

FILE 'HCAPLUS' ENTERED AT 13:52:36 ON 28 DEC 2009
L23 3 S L22
L24 1 S L23 AND (PY<2004 OR AY<2004 OR PRY<2004)

L24 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of imidazopyridine and imidazopyrimidine antiviral agents
GI



I



II

AB The title compds. [I; W = O, S; R1 = (CR'R'')nX; X = H, alkyl, cycloalkyl, etc.; n = 2-6; R2 = H, alkyl, cycloalkyl, etc.; R3-R6 = H, halo, alkyl, etc.; A, B, E, D = CH, CQ, N, NO; provided at least one of A, B, E or D is not CH or CQ; Q = halo, alkyl, alkyl substituted with 1-3 halogen atoms; R', R'' = H, alkyl, cycloalkyl, etc.], useful in the treatment of viral infections, more particularly, for the treatment of respiratory syncytial virus infection, were prepared Thus, reacting I [W = O; R1 = (CH2)3NH2; R2 = cyclopropyl; R3-R6 = H; E = N; A, B, D = CH] (preparation given) with N-chloroacetylurethane in the presence of Na2CO3 in MeCN afforded 39% II.TFA. The compds. I showed antiviral activity against RSV with EC50's between 50 μM and 0.001 μM vs. Ribavirin with an EC50 of 3 μM.

ACCESSION NUMBER: 2001:923615 HCAPLUS Full-text
DOCUMENT NUMBER: 136:37623

TITLE: Preparation of imidazopyridine and imidazopyrimidine antiviral agents

INVENTOR(S): Yu, Kuo-Long; Civiello, Rita L.; Combrink, Keith D.; Gulgeze, Hatice Belgin; Sin, Ny; Wang, Xiangdong; Meanwell, Nicholas A.; Venables, Brian Lee

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 196 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095910	A1	20011220	WO 2001-US14775	20010508 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020016309	A1	20020207	US 2001-840279	20010423 <--
US 6489338	B2	20021203		
CA 2412327	A1	20011220	CA 2001-2412327	20010508 <--
BR 2001011569	A	20030429	BR 2001-11569	20010508 <--
EP 1311268	A1	20030521	EP 2001-952114	20010508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004503501	T	20040205	JP 2002-510088	20010508 <--
HU 2004000766	A2	20040728	HU 2004-766	20010508 <--
AU 2001272906	B2	20040826	AU 2001-272906	20010508 <--
NZ 523566	A	20040827	NZ 2001-523566	20010508 <--

MX 2002012204 A 20031015 MX 2002-12204
20021210 <--
IN 2002MN01766 A 20050204 IN 2002-MN1766
20021210 <--
NO 2002005977 A 20030129 NO 2002-5977
20021212 <--
ZA 2002010104 A 20040312 ZA 2002-10104
20021212 <--
PRIORITY APPLN. INFO.: US 2000-211447P P
20000613 <--
US 2001-263363P P
20010122 <--
WO 2001-US14775 W
20010508 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:37623
IC ICM A61K031-495
ICS A61K031-50; A61K031-52; A61K031-44; A61P031-12; C07D471-02; C07D473-30; C07D487-02
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 10
IT 380602-42-6P 380602-45-9P 380602-46-0P 380602-47-1P 380602-53-9P
380602-62-0P 380602-74-4P 380602-76-6P 380602-77-7P
380602-78-8P 380603-02-1P 380603-09-8P 380603-10-1P 380603-11-2P
380603-12-3P 380603-13-4P 380603-15-6P 380603-24-7P 380603-29-2P
380603-35-0P 380603-39-4P 380603-43-0P 380603-45-2P 380603-47-4P
380603-51-0P 380603-59-8P 380603-61-2P 380603-66-7P 380603-69-0P
380603-70-3P 380603-74-7P 380603-80-5P 380603-89-4P 380603-96-3P
380604-04-6P 380604-06-8P 380604-13-7P 380604-17-1P 380604-41-1P
380604-43-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridine and imidazopyrimidine antiviral agents)
IT 380602-28-8P 380602-29-9P 380602-30-2P 380602-31-3P 380602-32-4P
380602-33-5P 380602-34-6P 380602-35-7P 380602-36-8P 380602-37-9P
380602-38-0P 380602-39-1P 380602-40-4P 380602-41-5P 380602-43-7P
380602-44-8P 380602-48-2P 380602-49-3P 380602-50-6P 380602-51-7P
380602-52-8P 380602-54-0P 380602-55-1P 380602-56-2P 380602-57-3P
380602-58-4P 380602-59-5P 380602-60-8P 380602-61-9P 380602-63-1P
380602-64-2P 380602-65-3P 380602-66-4P 380602-67-5P 380602-68-6P
380602-69-7P 380602-70-0P 380602-71-1P 380602-72-2P

380602-80-2P
380602-81-3P 380602-82-4P 380602-83-5P 380602-84-6P
380602-85-7P
380602-87-9P 380602-90-4P 380602-93-7P 380602-95-9P
380602-97-1P
380602-99-3P 380603-01-0P 380603-03-2P 380603-04-3P
380603-05-4P 380603-06-5P 380603-07-6P 380603-08-7P
380603-14-5P 380603-16-7P 380603-19-0P 380603-22-5P
380603-27-0P
380603-32-7P 380603-37-2P 380603-41-8P 380603-49-6P
380603-53-2P
380603-55-4P 380603-57-6P 380603-63-4P 380603-64-5P
380603-68-9P
380603-71-4P 380603-72-5P 380603-73-6P 380603-75-8P
380603-77-0P
380603-78-1P 380603-79-2P 380603-81-6P 380603-82-7P
380603-83-8P
380603-84-9P 380603-85-0P 380603-86-1P 380603-87-2P
380603-91-8P
380603-93-0P 380603-95-2P 380603-97-4P 380603-98-5P
380604-00-2P
380604-02-4P 380604-08-0P 380604-10-4P 380604-15-9P
380604-19-3P
380604-21-7P 380604-23-9P 380604-25-1P 380604-26-2P
380604-27-3P
380604-29-5P 380604-31-9P 380604-33-1P 380604-34-2P
380604-35-3P
380604-36-4P 380604-37-5P 380604-38-6P 380604-39-7P
380604-40-0P
380604-44-4P 380604-45-5P 380604-46-6P 380604-48-8P
380604-50-2P
380604-51-3P 380604-52-4P 380604-53-5P 380604-54-6P
380604-55-7P
380604-56-8P 380604-57-9P 380604-58-0P 380604-59-1P
380605-63-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES
(Uses)

L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 9 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:06:11 ON 28 DEC 2009
L4 16 S L3
L5 2 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'REGISTRY' ENTERED AT 15:07:09 ON 28 DEC 2009
E 380603-12-3/RN
SET EXPAND CONTINUOUS
L6 1 S E3
L7 1 S E10

```
                E 380603-70-3/RN
L8          1 S E15
L9          1 S E16
L10         1 S E13
```